Increased Drug Toxicity in Advanced Kidney Failure: Mechanisms & Dosing

In advanced CKD (GFR <30 mL/min) and ESKD, multiple pharmacokinetic and pharmacodynamic changes increase drug toxicity risk. Understanding these guides safer prescribing.

Key Mechanisms of Increased Toxicity

1. Reduced Renal Clearance (↓GFR)

Primary route of elimination for many drugs/metabolites. ↓GFR → ↑half-life → accumulation → toxicity. Applies to: renally excreted drugs (gabapentin, pregabalin, metformin, DOACs, many antibiotics), active metabolites (normeperidine, morphine-6-glucuronide).

2. Altered Protein Binding

CKD → ↓albumin, ↑uremic toxins displace drugs from albumin/α1-acid glycoprotein → ↑free (active) fraction → ↑volume of distribution (Vd) & ↑clearance for high-extraction drugs, but ↑effect for low-extraction drugs. Critical for: phenytoin, valproate, warfarin, furosemide.

3. Impaired Drug Metabolism

Uremia downregulates hepatic CYP450 enzymes (CYP3A4, CYP2C9, CYP2D6) and transporters (OATP, P-gp). ↓Metabolism → ↑levels for CYP substrates. Also alters prodrug activation (e.g., clopidogrel).

4. Altered Volume of Distribution (Vd)

↑Vd: Fluid overload, edema, ascites → hydrophilic drugs distribute into larger volume → ↓peak concentration but ↑total body load (e.g., aminoglycosides, vancomycin, beta-lactams).
↓Vd: Malnutrition, low muscle mass → ↓Vd for lipophilic drugs → ↑concentration.

5. Increased Pharmacodynamic Sensitivity

Uremia alters receptor sensitivity and homeostatic mechanisms. Examples:

  • ↑Sedation from opioids, benzodiazepines, gabapentinoids.
  • ↑Bleeding risk from antiplatelets/anticoagulants (uremic platelet dysfunction).
  • ↑Neurotoxicity from CNS-penetrant drugs.
  • ↑Hypotension from antihypertensives (autonomic neuropathy).

6. Dialysis Removal Variability

Intermittent hemodialysis clears small, water-soluble, low-protein-bound, low-Vd drugs. Requires supplemental dosing post-HD. Peritoneal dialysis has continuous but lower clearance.

Clinical Application

  • Use CKD dosing references (Lexicomp, UpToDate, FDA labels, KDIGO guidelines).
  • Prefer non-renal alternatives when possible.
  • Start low, go slow; monitor levels (vancomycin, aminoglycosides, digoxin, anticonvulsants).
  • Adjust for dialysis schedule (give after HD, not before).
  • Review medications at every transition (CKD stage change, dialysis initiation, transplant).

Kidney Disease - Related Articles